Strategic partnerships Belharra has a recent Sanofi collaboration (June 2024) indicating openness to tiered pharma partnerships and potential co-development or licensing discussions. Engage with Sanofi-aligned teams or explore analogous partnerships with biotech and specialty pharma targets.

CSO appointment New Chief Scientific Officer appointed (Sean Buchanan, Jan 2025), signaling potential leadership-driven prioritization and strategic pivots. Leverage conversations around platform capabilities and upcoming programs aligned with a fresh scientific direction.

Platform value Proprietary photoaffinity-based chemoproteomics platform claims to identify binding sites across the proteome and conformations, suggesting opportunities to partner on challenging targets and accelerated hit discovery for previously intractable diseases.

Financing momentum Seed/early-stage funding history includes a $50M Series A and $130M funding round; ongoing growth expectations and potential appetite for additional collaborations or investor-led partnerships to de-risk early programs.

Global footprint Headquartered in the San Francisco Bay Area with primary labs in San Diego, reflecting access to biotech ecosystems, talent, and potential co-location opportunities for joint research centers or sponsored discovery projects.